Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Abiraterone Acetate Tablets USP in the US market in 250 mg tablets in bottle count sizes of 120.
The company added that Abiraterone Acetate Tablets USP, 250 mg is the therapeutic equivalent generic version of Zytiga (abiraterone acetate), which has been approved by the US Food and Drug Administration (USFDA).
For the most recent 12 months ending in March 2020, Zytiga brand and generic market had US sales of about USD454m MAT, according to IQVIA Health.
Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer, added the company.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling